Clinical Trials
14
Active:7
Completed:3
Trial Phases
2 Phases
Phase 1:7
Phase 2:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (50.0%)Phase 2
7 (50.0%)A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Phase 2
Recruiting
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Drug: AP1189, 40 mgDrug: AP1189, 70 mgDrug: AP1189, 100 mgDrug: AP1189 matching placebo
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 240
- Registration Number
- NCT06671054
- Locations
- 🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: AP1189, 80 mgDrug: PlaceboDrug: AP1189, 100 mgDrug: AP1189, 60 mg
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 125
- Registration Number
- NCT05604885
- Locations
- 🇲🇩
Timofei Mosneaga Republican Clinical Hospital, Chișinău, Moldova, Republic of
A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: PlaceboDrug: 100 mg AP1189
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 127
- Registration Number
- NCT05516979
- Locations
- 🇲🇩
Timofei Mosneaga Republican Clinical Hospital, Chișinău, Moldova, Republic of
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
Phase 2
Recruiting
- Conditions
- Severe Proteinuria Due to Idiopathic Membranous NephropathyNephrotic Syndrome Due to Idiopathic Membranous Nephropathy
- Interventions
- Drug: PlaceboDrug: 100 mg AP1189
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 23
- Registration Number
- NCT04456816
- Locations
- 🇩🇰
Aarhus Universitetshospital, Aarhus, Denmark
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 105
- Registration Number
- NCT04004429
- Locations
- 🇩🇰
Aarhus Universitetshospital, Aarhus, Denmark
🇳🇴Diakonhjemmet Sykehus, Oslo, Norway
News
No news found